Danaher, a provider of ore bio-analytical and electronic measurement solutions, completed the acquisition of Precision NanoSystems, a developer of proprietary microfluidic devices designed for the simple, rapid, reproducible and cost-effective manufacture of next-generation lipid nanoparticles. Financial terms were not disclosed. "PNI has advanced a number of exciting innovations and we're thrilled to welcome this talented team. As mRNA has matured as a successful technology in some COVID vaccines, we're seeing huge potential for this technology Covid accelerate other therapies. The work done so far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients," Emmanuel Ligner, Danaher Group Executive.